Research and Discovery Archives - Page 2 of 4 - Lupus Research Alliance

Category: Research and Discovery

Better Survival Rates from Severe Lupus Nephritis

September 20, 2018 Significantly more people are surviving end-stage renal (kidney) disease caused by lupus nephritis according to a long-term analysis published in Arthritis & Rheumatology. The analysis of the national registry of 20,974 patients with end-stage renal disease (ESRD) during the years 1995 through 2014 found that mortality rates significantly declined. In addition, among […] Read More

Lupus Insight Prize Winner Finds Blood Pressure Drugs May Prevent Memory Loss in Lupus

September 7, 2018 We congratulate Dr. Betty Diamond of Feinstein Institute for Medical Research for her recently published work showing that ACE inhibitors, a specific type of hypertension drugs approved for lowering high blood pressure may prevent memory loss for people with lupus. With her 2018 Lupus Insight Prize from the Lupus Research Alliance, Dr. Diamond […] Read More

Our Grantees Lead Investigation of Microbiome in Lupus

Sept. 5, 2018 Our microbiome includes all of the trillions of microorganisms that live in and on us. A recent review article about key discoveries on the role of the microbiome in lupus includes two researchers funded by the Lupus Research Alliance who may have discovered how some of these microbial passengers promote lupus by […] Read More

Battling Lupus with Krill: Phospholipid-rich krill oil a potential new relief option for lupus

August 28, 2018 NEW YORK, NY. Aker BioMarine and Lupus Research Alliance launch a new clinical study, investigating how phospholipid-rich krill oil can benefit people with lupus, with the aim to lessen the severity of symptoms associated with the disease. Affecting an estimated 5 million people worldwide, Systemic Lupus Erythematosus (SLE), better known as lupus, […] Read More

Hearst Foundations Awards Grant to Lupus Research Alliance

August 22, 2018 The Lupus Research Alliance is proud to once again be awarded the Health Grant from the Hearst Foundations. In the amount of $150,000, the highly sought Health Grant will help support two promising investigators relatively new to lupus who were recently awarded our Novel Research Grants, Drs. Andrea Knight and Vipin Kumar. […] Read More

New Paper Confirms Lupus is a Dangerous Disease – a Leading Cause of Death for Young Women and Girls

August 9, 2018 The Lupus Research Alliance appreciates new published findings that finally document what we and the lupus community have long known only too well – lupus is a leading cause of death among women, particularly threatening the lives of our most vulnerable – children and teens. These findings propel our determination to provide […] Read More

Inflammation Trigger Discovery May Lead to New Treatment

August 2, 2018 Inflammation helps us repair injuries and defeat infections. It’s supposed to shut down once a crisis is over. In people with lupus, however, inflammation persists and can damage the joints, skin, and organs. Researchers have discovered a molecular sensor in cells known as the NLRP3 inflammasome that triggers inflammation. When the inflammasome […] Read More

By Studying How Killer Viruses Work Against Our Immune System, Lupus Research Alliance Funded Researcher May Have Found a New Way to Treat Lupus

July 26, 2018 By uncovering how some killer viruses beat our immune system, scientists partly funded by the Lupus Research Alliance have identified a potential new way to treat lupus. The viruses that cause Lassa fever and other similar diseases kill thousands of people every year. One reason these viruses are deadly is that they […] Read More

Scientific and Technology Breakthroughs Show Promise for Lupus and Other Immunologic Diseases

July 16, 2018. The Lupus Research Alliance is pleased and very encouraged to share a promising scientific breakthrough reported in the New York Times with real potential to revolutionize lupus treatment. Just reported in the prestigious journal Nature, scientists in Dr. Alexander Marson’s lab at the University of California, San Francisco have developed an innovative […] Read More

Neovacs Announces the Results of its Phase IIb Study for Ifnalpha Kinoid in the Treatment of Lupus Which Allows to Proceed With the Clinical Development into Phase III

July 3, 2018 Neovacs announced the results of its Phase IIb clinical trial of the investigational agent IFNalpha Kinoid in patients with moderate to severe lupus (SLE). The results show that IFNalpha Kinoid very significantly reduced the levels of type I interferon genes in the blood and tissue cells of people with lupus. High levels […] Read More

because the Lupus Research Alliance board of directors funds all administrative and fundraising costs